Oncology Bytes: Key Highlights from ASCO GU 2026 with Dr Shreyas Kalantri

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
???? Oncology Bytes | ASCO GU 2026

In this episode of Oncology Bytes, Dr. Shreyas Kalantri shares his key takeaways from ASCO GU 2026, focusing on major clinical trials that are shaping the future of genitourinary oncology.

???? Key highlights discussed:

- KEYNOTE-B15: Perioperative Enfortumab vedotin + Pembrolizumab showing improved outcomes compared with Cisplatin-based chemotherapy in muscle-invasive bladder cancer.The growing discussion around bladder preservation strategies driven by high pathological complete response rates.
Reference Link: https://www.asco.org/abstracts-presentations/256834

- LITESPARK-022: Adding Belzutifan to adjuvant Pembrolizumab reducing recurrence risk in high-risk clear-cell renal cell carcinoma. Reference Link: https://www.asco.org/abstracts-presentations/256660

- LITESPARK-011: Belzutifan plus Lenvatinib showing improved progression-free survival versus Cabozantinib in metastatic RCC after PD-1 therapy. Reference Link: https://www.asco.org/abstracts-presentations/256659

- PEACE-3 trial: Enzalutamide combined with Radium-223 demonstrating overall survival benefit in metastatic castration-resistant prostate cancer. Reference Link: https://www.asco.org/abstracts-presentations/256362

???? A key theme emerging from ASCO GU 2026: Can we intensify treatment earlier to improve outcomes while balancing toxicity and patient selection?

???? Oncology at your fingertips.
Download the ONCOassist app:
???? iOS: https://apple.co/4iuMxfS
???? Android: https://bit.ly/oncoassistonandroid
????Webapp: https://bit.ly/ONCOassistOnWeb

???? Learn more at: https://oncoassist.com/
???? SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights!
???? Turn on notifications so you never miss an episode.
???? FOLLOW US FOR UPDATES:
???? LinkedIn: https://bit.ly/oncoassistlinkedin
???? Twitter/X: https://bit.ly/oncoassisttwitter

#OncologyBytes #ASCOGU #GenitourinaryOncology #CancerResearch #MedicalOncology #ONCOassist #GU26 #Oncoalert
Categoria
Oncology
Commenta per primo questo video.

Prossimo